Journal article
Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
Abstract
BACKGROUND: Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and genotype based EFV dose recommendations for adult HIV-1 infected Ugandans.
METHODS: In total, 556 steady-state plasma EFV concentrations from 99 HIV infected …
Authors
Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
Journal
PLOS ONE, Vol. 9, No. 1,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pone.0086919
ISSN
1932-6203
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
ATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1AdultAlkynesArea Under CurveAryl Hydrocarbon HydroxylasesBenzoxazinesCyclopropanesCytochrome P-450 CYP2B6Cytochrome P-450 CYP3ADose-Response Relationship, DrugDrug Therapy, CombinationFemaleGenotypeHIV InfectionsHumansLamivudineMaleMiddle AgedMutationPharmacogeneticsReverse Transcriptase InhibitorsTreatment OutcomeUgandaZidovudine